JPRN-jRCT2080221877未知1 期
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Patients With Castration-Resistant Prostate Cancer
适应症
试验速览
- 阶段
- 1 期
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- Male
入选标准
- •Histologically or cytologically confirmed diagnosis of prostate adenocarcinoma
- •- Progressive disease
- •- Prior surgical castration or concurrent use of an agent for medical castration
- •- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
排除标准
- •- Received prior chemotherapy for prostate cancer
- •- Documented central nervous system metastases
- •- Current spinal cord compression, bilateral hydronephrosis or current bladder neck outlet obstruction
- •- Uncontrolled cardiovascular condition as specified in study protocol
- •- Uncontrolled nausea, vomiting or diarrhea
研究者
相似试验
进行中（未招募）
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001539-30-NLMillennium Pharmaceuticals, Inc.144
已完成
2 期
A Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naïve Patients With Castration-Resistant Prostate Cancercastrationresistant prostate cancer (mCRPC)chemotherapy-naïvemetastaticprogressiveprostate cancer1003859310036958NL-OMON37312Millenium Pharmaceuticals8
进行中（未招募）
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 14.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001539-30-GRMillennium Pharmaceuticals, Inc.144
进行中（未招募）
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 14.1 Level: SOC Classification code 10029104 Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps) System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001539-30-GBMillennium Pharmaceuticals, Inc.137
进行中（未招募）
1 期
Study to find out the effects and fate of treatment with Orteronel plus prednisone in Japanese and non Japanese people that have not recieved cancer therapy for prostate cancer.progressive castration-resistant prostate cancer.MedDRA version: 16.1Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2012-001539-30-IEMillennium Pharmaceuticals, Inc.144